Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,382 across all filing types
Latest filing 2015-02-03 Earnings Release
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Earnings Release Classification · 95% confidence The document is an initial announcement of Ipsen's sales performance for the fourth quarter and full year 2014. It provides key financial highlights, sales breakdowns by region and therapeutic area, and commentary from the CEO. It is not a full annual report (10-K) or a comprehensive interim report (IR) containing full financial statements, but rather a summary of sales results. According to the filing definitions, this fits the 'Earnings Release' (ER) category as it focuses on the initial announcement of period-specific financial results and key highlights. FY 2014
2015-02-03 English
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 99% confidence The document is titled "Ipsen : chiffre d'affaires du 4ème trimestre et de l'année 2014" (Ipsen: Revenue for the 4th Quarter and the Year 2014) and contains detailed financial tables showing revenue figures for Q4 2014 and the full year 2014, broken down by geography and therapeutic area. It explicitly states that Ipsen "a publié aujourd'hui son chiffre d'affaires pour le quatrième trimestre et l'année 2014." This content structure—a detailed release of periodic financial results (quarterly and annual figures) accompanied by management commentary—is characteristic of an Earnings Release (ER). Although it contains comprehensive data, it is presented as a press release announcing the results, not the full, audited Annual Report (10-K) or a comprehensive Interim Report (IR) which typically follows a specific regulatory filing format. Since it is the initial announcement of periodical financial results, ER is the most appropriate classification. Q4 2014
2015-02-03 French
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Regulatory Filings Classification · 95% confidence The document announces the 'topline results' of two Phase III clinical studies for a drug (Dysport®) in treating spasticity. It details primary and secondary endpoints, safety profiles, and quotes investigators. This type of announcement, focusing on the immediate release of key clinical trial outcomes, is characteristic of an Earnings Release (ER) or a specific type of press release announcing scientific progress. Since the document is a detailed press release announcing specific clinical trial results (not a general financial summary, a full annual report, or a transcript), it aligns best with the 'Earnings Release' (ER) category, which often includes key operational/scientific milestones alongside financial updates, or sometimes a specific 'Regulatory Filing' (RNS) if it were a required submission. Given the focus on announcing 'topline results' and the date (Jan 26, 2015), it functions as a major operational/scientific update press release. However, none of the definitions perfectly capture a 'Clinical Trial Result Announcement'. Comparing the options: it is not a 10-K, AR, CT, or IR. It is a detailed announcement, not just a link (ruling out RPA/RNS based on the 'Menu vs Meal' rule if it were short, but this is a substantial document). Since it details key performance indicators (study results) released to the public, ER is the closest fit for a major operational announcement, although it is heavily scientific. If a more specific category existed for R&D updates, that would be chosen. Given the provided list, ER covers the release of key period/operational performance highlights.
2015-02-03 English
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 95% confidence The document is a press release dated January 26, 2015, announcing preliminary results from two Phase III clinical studies for the drug Dysport®. It details efficacy endpoints (Modified Ashworth Scale, MAS) and safety profiles, includes quotes from R&D leadership and principal investigators, and provides background information on the drug and the company (Ipsen). This content structure—announcing key clinical trial results outside of a formal quarterly or annual financial filing—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/scientific news. Since it focuses specifically on announcing financial/operational results (clinical trial outcomes which drive future revenue/valuation) rather than being a full financial report (10-K, IR) or a transcript (CT), the most appropriate classification is Earnings Release (ER), as these announcements often precede or accompany formal earnings reports. It is not a 10-K (Annual Report), IR (Interim Report), or MDA (Management Discussion & Analysis). It is not a CT (Call Transcript) as it is a written announcement. It is not an RPA because it contains the substantive results, not just an announcement that a report is available. FY 2015
2015-02-03 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 95% confidence The document is a press release dated January 26, 2015, announcing preliminary results from two Phase III clinical studies for the drug Dysport®. It details efficacy endpoints (Modified Ashworth Scale, MAS) and safety profiles, includes quotes from R&D leadership and principal investigators, and provides background information on the drug and the company (Ipsen). This content structure—announcing key clinical trial results outside of a formal quarterly or annual financial filing—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/scientific news. Since it focuses specifically on announcing financial/operational results (clinical trial outcomes which drive future revenue/valuation) rather than being a full financial report (10-K, IR) or a transcript (CT), the most appropriate classification is Earnings Release (ER), as these announcements often precede or accompany formal earnings reports. It is not a 10-K (Annual Report), IR (Interim Report), or MDA (Management Discussion & Analysis). It is not a CT (Call Transcript) as it is a written announcement. It is not an RPA because it contains the substantive results, not just an announcement that a report is available. FY 2015
2015-01-26 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document announces the 'topline results' of two Phase III clinical studies for a drug (Dysport®) in treating spasticity. It details primary and secondary endpoints, safety profiles, and quotes investigators. This type of announcement, focusing on the immediate release of key clinical trial outcomes, is characteristic of an Earnings Release (ER) or a specific type of press release announcing scientific progress. Since the document is a detailed press release announcing specific clinical trial results (not a general financial summary, a full annual report, or a transcript), it aligns best with the 'Earnings Release' (ER) category, which often includes key operational/scientific milestones alongside financial updates, or sometimes a specific 'Regulatory Filing' (RNS) if it were a required submission. Given the focus on announcing 'topline results' and the date (Jan 26, 2015), it functions as a major operational/scientific update press release. However, none of the definitions perfectly capture a 'Clinical Trial Result Announcement'. Comparing the options: it is not a 10-K, AR, CT, or IR. It is a detailed announcement, not just a link (ruling out RPA/RNS based on the 'Menu vs Meal' rule if it were short, but this is a substantial document). Since it details key performance indicators (study results) released to the public, ER is the closest fit for a major operational announcement, although it is heavily scientific. If a more specific category existed for R&D updates, that would be chosen. Given the provided list, ER covers the release of key period/operational performance highlights.
2015-01-26 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.